SCHEMBL31269259

SCHEMBL31269259

CC1(Oc2nc(C(N)=O)nc3c2nc(Br)n3Cc2ccccc2)CCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 2/20 0.41
▸ ADORA1 P30542 2/20 0.41
▸ ALDH1A1 P00352 4/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ TSHR P16473 3/20 0.36
▸ GAA P10253 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ CASP1 P29466 2/20 0.36
▸ CASP7 P55210 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ GLA P06280 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ TLR7 Q9NYK1 2/20 0.34
▸ PDE8B O95263 1/20 0.34
▸ RAB9A P51151 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ TMIGD3 P0DMS9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30984035 0.96 ADORA2A (0.42) ADORA2AADORA1ALDH1A1KDM4ETSHR
SCHEMBL30984102 0.81 ADORA2A (0.56) ADORA2AADORA1TMIGD3ADORA2B
SCHEMBL30984101 0.81 ADORA2A (0.56) ADORA2AADORA1TMIGD3ADORA2B
Lithium SCHEMBL30983994 0.80 ADORA2A (0.55) ADORA2AADORA1TMIGD3ADORA2B
SCHEMBL31321972 0.65 PIK3CD (0.38) ADORA2AADORA1
SCHEMBL5732024 0.63 ADORA2A (0.65) ADORA2AADORA1KDM4ETSHRHSD17B10
SCHEMBL7204696 0.63 ADORA2A (0.61) ADORA2AADORA1ALDH1A1KDM4EHPGD
SCHEMBL7205701 0.63 ADORA2A (0.61) ADORA2AADORA1TLR7TMIGD3ADORA2B
SCHEMBL7204601 0.63 ADORA2A (0.60) ADORA2AADORA1ALDH1A1HPGDLMNA
SCHEMBL2060194 0.63 TLR7 (0.55) ADORA2AADORA1TLR7TMIGD3ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback